Stocks making the biggest moves premarket: Verizon, Tesla, Moderna & more

Premarket moves were mixed: Range Resources jumped 15% after EQT announced an all-stock acquisition valuing it at more than $50 billion, while EQT fell 4%; Surgery Partners surged nearly 25% on a report of a potential $6 billion take-private deal at $20 per share. Verizon rose 2% after a Q3 earnings beat and higher full-year 2026 guidance, while Meta gained 1% after announcing a $35 billion stock offering and plans for a separate $60 billion at-the-market program. On the downside, Moderna fell 8% as selling continued after leaked cancer-vaccine study results, and Fair Isaac dropped nearly 10% after a downgrade tied to its decision not to raise FICO-score prices.

Analysis

The tape is rewarding near-term earnings visibility while repricing financing and execution risk. For neoclouds, Musk’s comment is not evidence of customer churn, but it may raise the cost of capital for smaller or less contracted operators: if funding tightens, price competition and customer concentration become more consequential for CoreWeave, Nebius and IREN. Avoid treating the group as interchangeable; backlog quality, utilization and funding access are the key differentiators.

Meta’s equity financing reduces reliance on debt but creates potential supply overhang and makes AI returns more central to the valuation debate. The test over 1–3 months is whether capex converts into measurable monetization, not whether the build-out continues. Tesla’s upgrade case appears partly dependent on speculative transaction optionality; treat that as non-core until there is company-confirmed evidence. Verizon’s guidance can support a defensive re-rating, but verify cash-flow conversion against capex and debt costs.

The Range/EQT transaction creates a deal-spread and integration question, not an automatic win for either side: all-stock consideration exposes Range holders to EQT’s share price through closing, while Appalachian concentration and commodity/basis exposure could offset scale benefits. Surgery Partners remains binary on an unconfirmed report. FICO’s pricing restraint may protect retention now but risks weakening the long-term pricing-power narrative; lender adoption and renewal terms matter. Moderna’s reaction is vulnerable to further repricing until complete study data clarify efficacy and safety. ROST’s productivity thesis needs confirmation in comparable-store sales and margins.

Key Decisions for Investors

• Neoclouds: Do not short the basket solely on the social-media quote. Over the next 1–3 months, favor relative-value exposure only after checking contracted backlog, customer concentration, utilization, debt maturities and committed financing. Falsifier: stable financing access and utilization alongside resilient pricing; thesis strengthens if refinancing terms worsen or customers defer capacity.
• Meta: Keep exposure sized for dilution and execution risk rather than extrapolating the share reaction. Track the final issuance terms, share count impact, capex trajectory and evidence of AI-driven revenue or engagement monetization. Reassess if spending rises without improving returns or if issuance materially exceeds the market’s absorption capacity.
• Event risk: Treat Surgery Partners as a watch, not a confirmed take-private. A deal-arbitrage position requires an announced agreement, verified consideration and current price; absent that, the downside on a failed report is not bounded by the rumored value. For Range/EQT, wait for the exchange ratio and deal protections before considering a hedged merger-spread trade.
• FICO/MRNA: Avoid chasing either gap before fundamental verification. For FICO, monitor lender renewals, score adoption and pricing terms; for Moderna, obtain the full cancer-vaccine dataset and assess whether the leak changes the risk-adjusted pipeline value. Reversal signals are stable FICO retention/pricing or complete Moderna data that materially improve the efficacy and safety read-through.